Abstract

Glucocorticoids (GCs) are potent repressors of NF-κB activity, making them a preferred choice for treatment of inflammation-driven conditions. Despite the widespread use of GCs in the clinic, current models are inadequate to explain the role of the glucocorticoid receptor (GR) within this critical signaling pathway. GR binding directly to NF-κB itself—tethering in a DNA binding-independent manner—represents the standing model of how GCs inhibit NF-κB-driven transcription. We demonstrate that direct binding of GR to genomic NF-κB response elements (κBREs) mediates GR-driven repression of inflammatory gene expression. We report five crystal structures and solution NMR data of GR DBD-κBRE complexes, which reveal that GR recognizes a cryptic response element between the binding footprints of NF-κB subunits within κBREs. These cryptic sequences exhibit high sequence and functional conservation, suggesting that GR binding to κBREs is an evolutionarily conserved mechanism of controlling the inflammatory response.

Details

Title
Cryptic glucocorticoid receptor-binding sites pervade genomic NF-κB response elements
Author
Hudson, William H 1 ; Ian Mitchelle S de Vera 2 ; Nwachukwu, Jerome C 3   VIAFID ORCID Logo  ; Weikum, Emily R 4 ; Herbst, Austin G 5 ; Yang, Qin 6 ; Bain, David L 6 ; Nettles, Kendall W 3 ; Kojetin, Douglas J 7   VIAFID ORCID Logo  ; Ortlund, Eric A 4 

 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Discovery and Developmental Therapeutics, Winship Cancer Institute, Atlanta, Georgia, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA 
 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, USA 
 Department of Integrated Structural and Computational Biology, The Scripps Research Institute, Jupiter, Florida, USA 
 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Discovery and Developmental Therapeutics, Winship Cancer Institute, Atlanta, Georgia, USA 
 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA 
 Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA 
 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA 
Pages
1-13
Publication year
2018
Publication date
Apr 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2022520648
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.